Filament Health To Discuss Its Drug Development Platform in Fireside Chat With Water Tower Research on April 4, 2024 at 12PM ET | Psychedelic Invest

VANCOUVER, BC, March 19, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, announced that since March 1, 2024 it has shipped its botanical psilocybin drug candidate, PEX010, to four countries for clinical trials at leading research institutions. PEX010 will be studied in Canada, the United States, Belgium, and Israel, for…

CAN-3110 by Candel Therapeutics for High-Grade Glioma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

July 7, 2024

Suicidal Ideation Common Among Transgender, Gender Diverse Youth in ED

WASHINGTON — A keyword-based search in the electronic medical record (EMR) at an urban emergency department (ED) showed high rates of suicidal ideation among transgender

October 25, 2023

How efforts to cancel medical debt could wind up benefitting hospitals

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in

September 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.